Vera Therapeutics (VERA) executive Young acquired 5,000 shares at $3.94
Insider transactions reported
Joseph R Young (SVP, Finance, Chief Acct Offcr at Vera Therapeutics Inc., VERA) reported that they acquired 5,000 shares at $3.94 on Sep 11, 2026. After these transactions the filing shows 80,754 shares held directly.
- Reporting person
- Young Joseph R
- Role
- SVP, FINANCE, CHIEF ACCT OFFCR
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Exercise or conversion of a derivative (M) | Class A Common Stock | +5,000 | $3.94 | $19.7K | 80,754 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Exercise or conversion of a derivative (M) | Stock Option (right to buy)On 5,000 Class A Common Stock1 | -5,000 | - | - | 33,589 direct |
Holdings before and after
- Class A Common Stock: 75,754 to 80,754 direct
- Stock Option (right to buy): 38,589 to 33,589 direct
Footnotes from the filing
- 1. 1/4 of the shares subject to the option vested on March 9, 2022, and 1/48 of the shares vest monthly thereafter.
Transaction codes in this filing
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
FAQ
What did Young report in this VERA Form 4?
Joseph R Young (SVP, Finance, Chief Acct Offcr at Vera Therapeutics Inc., VERA) reported that they acquired 5,000 shares at $3.94 on Sep 11, 2026. After these transactions the filing shows 80,754 shares held directly.
How many VERA shares does Young hold after this filing?
The filing shows 80,754 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code M mean on an SEC Form 4?
Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
Historical context for VERA
Across the 30 sessions after earlier VERA headlines, the stock closed higher 14 times and lower 16 times, with a median move of 1.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | VERA | SPY |
|---|---|---|---|
| Sep 8, 2026 | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -1.7% | -0.5% |
| Sep 1, 2026 | Vera Therapeutics to Participate at Upcoming Investor Conferences | +0.4% | -0.7% |
| Aug 11, 2026 | Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | -4.1% | -0.3% |
| Aug 10, 2026 | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -4.0% | -0.0% |
| Jul 13, 2026 | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -1.2% | -0.8% |
| Jul 9, 2026 | Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner | +0.0% | +0.8% |
Earlier insider filings at VERA
- Sep 4, 2026PRESIDENT AND CEO Fordyce Marshall exercised 18,500 shares at a strike of $2.90 and sold $649,642 worth of shares (18,500 units at $35.12) as part of a pre-agreed trading plan (SEC Form 4)
- Aug 12, 2026Amendment: PRESIDENT AND CEO Fordyce Marshall exercised 46,250 shares at a strike of $2.90 and sold $1,956,187 worth of shares (46,250 units at $42.30) as part of a pre-agreed trading plan (SEC Form 4)
- Aug 12, 2026Amendment: PRESIDENT AND CEO Fordyce Marshall exercised 18,500 shares at a strike of $2.90 and sold $701,769 worth of shares (18,500 units at $37.93) as part of a pre-agreed trading plan (SEC Form 4)
- Aug 12, 2026Amendment: PRESIDENT AND CEO Fordyce Marshall exercised 18,500 shares at a strike of $2.90 and sold $679,747 worth of shares (18,500 units at $36.74) as part of a pre-agreed trading plan (SEC Form 4)
- Aug 5, 2026Chief Regulatory Officer Boman Nancy Lee was granted 44,987 shares (SEC Form 4)
Keep researching VERA
- VERA insider tradesEvery buy and sale reported by Vera Therapeutics Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- VERA earnings historyPast Vera Therapeutics Inc. earnings releases, newest first.
- VERA financial statementsRevenue, profit, cash flow and balance sheet from Vera Therapeutics Inc.'s SEC filings.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Follow VERA and get a push notification the moment its next story breaks.